nektar.comNektar | Home | New Pathways to Smarter Medicine

SEARCH MEDIA CAREERS CONTACT Our Company Our Story Our Leadership Our Board of Directors Our Partners Locations Contact Our Pipeline ASCO Virtual Booth R&D Pipeline Bempegaldesleukin (NKTR-214) Dapirolizumab Pegol (Anti-CD40L) NKTR-358 NKTR-262 NKTR-255 Clinical Trials Expanded Access Investigator Supported Trials Our Medicines U.S. Medicines Marketed by Our Partners EU Medicines Marketed by Our Partners Investigational Medicines Our Science Research Platform Scientific & Clinical Data Presentations Scientific & Medical Events Investors About Us Press Releases Investor Events Stock Information Historic Stock Lookup Analyst Coverage Financials & Filings SEC Filings Annuals and Proxies Quarterly Results Corporate Governance Investor Contacts E-mails Alerts Media Media Room Video Gallery Image Gallery Careers Life at Nektar Search Jobs Search Jobs (Mobile Device) Benefits at Nektar Benefits at San Francisco, California Benefits at Huntsville, Alabama Benefits at Hyderabad, India Information for Recruiters -- OUR COVID-19 RESPONSE – Updated May 7, 2020 New Pathways To Smarter Medicine TM Cutting-edge chemistry. Life-changing biology. TM Icon1 Icon2 Icon3 Bringing hope to millions of patients by creating new medicines that treat serious medical needs. More Improving human health through the power of a revolutionary chemistry platform. More Developing groundbreaking therapies by unleashing the true potential of critical biological pathways. More -- Events JUN 05 Conference Call for Analysts at EULAR Virtual 11:00 AM EDT Listen to Webcast Presentation Slides MAY 07 Q1 2020 Financial Results San Francisco, CA 17:00 Eastern Time Conference ID: 8288857 Webcast Link MAR 03 Cowen 40th Annual Health Care Conference Boston, MA 9:20 a.m. ET/6:20 a.m. PT Presentation - 9:20 a.m. ET/6:20 a.m. PT Listen to Webcast 10:00 a.m. ET/7:00 a.m. PT Listen to Webcast Leadership Spotlight Dr. Jonathan Zalevsky, Chief Research & Development officer discusses bempegaldesleukin (NKTR-214) Watch Latest News OUR PIPELINE We are focused on using new chemistry approaches to make better medicines to treat cancer and auto-immune disease. Bempegaldesleukin IMMUNO-ONCOLOGY PHASE 3 NKTR-255 IMMUNO-ONCOLOGY PHASE 1 NKTR-358 AUTO-IMMUNE PHASE 1B 9 9 million patients benefit from our medicines 12 12 approved products around the world 10 10 new medicines in development pipeline Cutting-edge facilities Dynamic teams Impactful work OUR Culture We are supported by a dynamic team, rich in scientific, business and medical expertise, across three locations. Read more QUICK LINKS Our Company Our Pipeline Our Medicines Our Science Investors Media Careers Contact Privacy Terms of Use CONNECT LOCATIONS San Francisco, CA Huntsville, AL Hyderabad, India Copyright Nektar © 2020 -- OKAY GO BACK...